Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
These studies can guide doctors in identifying which patients might be more prone to urinary side effects
Data from industry GLP-1 clinical trials show that ~9 to 15% of participants* were not able to achieve weight reductions of 5% or greater Evidence continues to support that improved nutrition and regular physical activity are needed to promote healthy outcomes
Because GLP-1s are delivered at home, they fall under pharmacy benefits but many payers only cover them for diabetes, not for weight loss
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, was selected as an active-comparator placebo proxy because it was recommended in clinical guidelines as a second-line glucose-lowering therapy, had a similar high cost to the study drugs, showed no effect on cardiovascular outcomes in a large randomized controlled trial and has been validated as a placebo proxy in prior claims-based research 20,41
In this article, we compare and contrast four prominent injectable medicationsGLP-1, Ozempic, Wegovy, and Trulicityin terms of their mechanisms of action, clinical efficacy, and implications for weight management and glycemic control
Adults with excess visceral fat: particularly those who carry fat primarily in the midsection despite reasonable diet and exercise habits
